Jagsonpal Pharmaceuticals Limited
Quality (72/100) does the heavy lifting; valuation (37/100) is the drag.
Fair valueOur blended model reads Jagsonpal Pharmaceuticals Limited as a Hold at 58/100. At ₹242.29 it trades above our blended DCF and relative-multiples fair value of ₹195.06, about 19% downside to that estimate — we read it as overvalued by 19%. On 36.4x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. It's trading right at its 52-week high of ₹243.97. Financial health scores 95/100. It clears 9 of 12 investability checks, with durability 72, valuation 56 and momentum 63 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹156.05.
1-year price
EOD · 2026-09-2552-week range
-0.69% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold58Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 16.7%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 10%
- Pass: Earnings growing: 24%
- Pass: Net margin ≥ 10%: 15.0%
- Pass: Current ratio > 1.5: 5.06
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- Pass: Positive 1-year return
- No data: Altman Z in safe zone
- No data: Piotroski ≥ 7
Shareholding
- Promoter77.7%
- Institutions2.6%
- Public & other19.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
Opportunities
- Earnings growing (24% YoY).
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals manufactures and trades pharmaceutical products and active pharmaceutical ingredients for domestic and international markets. The company produces formulations in gynaecology, orthopaedics, dermatology, and paediatrics, delivered as tablets, softgels, injections, capsules, and syrups.
Jagsonpal Pharmaceuticals Limited — frequently asked questions
Is Jagsonpal Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) a Hold, based on a blended score of 58/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Jagsonpal Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates Jagsonpal Pharmaceuticals Limited's fair value at about ₹195.06, versus a current price of ₹242.29 — roughly 19% downside. On that basis the stock looks overvalued by 19%.
Is Jagsonpal Pharmaceuticals Limited financially healthy?
Jagsonpal Pharmaceuticals Limited scores 95/100 on our financial-health model.
How has Jagsonpal Pharmaceuticals Limited's share price performed?
Jagsonpal Pharmaceuticals Limited is up 5% over the past year and up 3% over three months, and last traded at ₹242.29. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.